Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-05-27
2008-05-27
O'Hara, Eileen (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000
Reexamination Certificate
active
07378385
ABSTRACT:
GLP-1 and GLP-1 receptor antagonists have been found to have a sedative or anxiolytic effect on the mammalian central nervous system. Conversely, GLP-1 and GLP-1 receptor agonists increase nervous system activity and the stress response. The invention relates, in one aspect, to the use of GLP-1 agonists and antagonists to modulate the stress response in a mammal. In an aspect GLP-1 and GLP-1 receptor antagonists are used to treat stress-related disorders.
REFERENCES:
patent: 5846937 (1998-12-01), Drucker
patent: 6395767 (2002-05-01), Robl et al.
van Dijk et al. Nature, 1997; 385:214.
Griebel et al. PNAS 2002; 99: 6370-6375.
Argyropoulos et al. (Pharmacology & Therapeutics, 2000; 88: 213-227.
Bruce S. McEwen, Brain Res. 2000; 886: 172-189.
Goke et al., Distribution of GLP-1 Binding Sites in the Rat Brain: Evidence that . . . , Eur. J. Neurosci, 1995, 7:2294-300.
Kinzig et al., CNS Glucagon-Like Peptide-1 Receptors Mediate Endocrine and Anxiety . . . , Journal of Neuroscience, Jul. 16, 2003, 23(15):6163-6170.
Thiele, et al., Research report on Central infusion of glucagon-like peptide-1-(7-36) amid (GLP-1) receptor antagonist attenuates lithium chloride-induced c-Fos induction in rat brainstem, Brain Research 801, 1998, pp. 164-170, Elsievier Science B.V.
Montrose-Rafizadeh, et al., High Potency Antagonists of the Pancreatic Glucagon-like Peptide-1 Receptor, The Journal of Biological Chemistry, vol. 272, No. 34, Aug. 22, 1997, pp. 21201-21206, U.S.A.
D'Alessio David A.
Kinzig Kimberley P.
Seeley Randy John
Borgeest Christina
O'Hara Eileen
Taft Stettinius & Hollister LLP
University of Cincinnati
LandOfFree
Role for GLP-1 to mediate responses to disparate stressors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Role for GLP-1 to mediate responses to disparate stressors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Role for GLP-1 to mediate responses to disparate stressors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2802454